Form 4: BioCryst CLO Alane Barnes Reports Equity Awards

BioCryst Pharmaceuticals' Chief Legal Officer, Alane P. Barnes, reported the acquisition of 121,700 restricted stock units and 255,050 employee stock options.

Summary

• Alane P. Barnes, Chief Legal Officer of BioCryst Pharmaceuticals, Inc. (BCRX), reported changes in her beneficial ownership.
• She acquired 121,700 shares of Common Stock as an annual award of restricted stock units on December 17, 2025.
• These restricted stock units will vest 25% on each of the first, second, third, and fourth anniversaries of the grant date.
• She also acquired 255,050 Employee Stock Options with an exercise price of $7.13 on December 17, 2025.
• These options become exercisable at a rate of 25% on each of the first, second, third, and fourth anniversaries of the grant date and expire on December 17, 2035.
• Following these transactions, Alane P. Barnes directly beneficially owns 437,426 shares of Common Stock and 255,050 derivative securities (Employee Stock Options).
• A Power of Attorney, dated June 11, 2025, was granted to Alane P. Barnes and Sara A. Mykrantz to prepare and file SEC reports on behalf of the undersigned.

Sentiment

Score: 7

Explanation: The filing is a routine disclosure of executive equity compensation, which is generally a positive sign of executive alignment with shareholder interests, but it does not contain new operational or financial news.

Positives

• The Chief Legal Officer received significant equity awards (121,700 restricted stock units and 255,050 stock options), which aligns her interests with those of shareholders.
• The awards are subject to a four-year vesting schedule, indicating a long-term commitment from the executive to the company's future performance.

Future Outlook

The vesting schedules for the restricted stock units and stock options extend over four years, indicating a future commitment and alignment of executive incentives with long-term company performance.

Industry Context

The granting of equity awards to executives is a common practice across industries, particularly in biotechnology and pharmaceuticals, to attract, retain, and incentivize key personnel. These awards align executive compensation with shareholder value creation and long-term company performance.

Comparison to Industry Standards

• The structure of equity awards, including restricted stock units and stock options with multi-year vesting, is standard practice for executive compensation in the biotechnology sector.
• This approach is comparable to practices at other publicly traded biotechnology companies, which utilize long-term incentive plans to retain talent and align executive interests with shareholder value creation.

Corporate Governance

Related Party Transactions

• The filing details equity awards (restricted stock units and stock options) granted to Alane P. Barnes, the Chief Legal Officer, as part of her compensation package.

Stakeholder Impact

• Shareholders: The equity awards align management's interests with shareholders, potentially fostering long-term value creation.
• Management: The Chief Legal Officer receives significant long-term incentives, reinforcing her commitment to the company.

Next Steps

• Vesting of restricted stock units and exercisability of stock options on the first, second, third, and fourth anniversaries of December 17, 2025.

Key Dates

Keywords

BioCryst Pharmaceuticals, BCRX, Alane P. Barnes, Chief Legal Officer, Form 4, insider transaction, equity awards, restricted stock units, stock options, beneficial ownership, SEC filing